What is Optimal Blood Pressure?

In the last 30 years, the clinical practice guidelines on both sides of the Atlantic have been lowering blood pressure thresholds. From the starting 160 mmHg systolic blood pressure to 130 mmHg or even 120 mmHg. 

Las nuevas guías Europeas de Hipertensión contrastan con las Americanas

In 2017, the American and the ACC/AHA guidelines were the first to lower said threshold, followed by the European ESC/ESH in 2018 and more recently by the National Institute for Health and Care Excellence (NICE) in August 2019.

With several points in common, they also differ in recommendations. The blood pressure target is still controversial, with 120 mmHg in patients for the ACC/AHA, 120-129 for the young and 130-139 mmHg for the elderly in the European guidelines, and the classic 140/90 for the conservative NICE guidelines.

With the kidneys as one of the main blood pressure targets, the new markers of lesion, inflammation and tubule fibrosis could be the ones to tell the adequate blood pressure threshold for each patient. 


Read also: Secondary Prevention: A Responsibility We Should Not Delegate.


The SPRINT study assessed 2377 hypertensive patients measuring alfa1 and beta2 microglobulin concentration, which was associated with major cardiovascular events, while uromodulin showed an inverse correlation.

Alfa 1 microglobulin twice as high as baseline was associated to the classic major events composite (death, infarction, stroke) as well as separate mortality, with 1.25 HR.

A two-fold higher uromodulin concentration was associat3ed to significant reduction of combined events, with HR 0.79, but this was not enough to reduce mortality considered separately. 


Read also: Benefit of Anticoagulation in the Elderly with Atrial Fibrillation.


The clinical value of these markers to adjust the “ideal” threshold in our patients should be further and discussed and studied.

Original Title: What is the optimal blood pressure?Differences between current guidelines and novel insights into kidney injury.

Reference: Thomas F. Lüscher. European Heart Journal (2019) 40, 3443–3446.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Low-Dose Rivaroxaban After Peripheral Angioplasty: Effectiveness and Safety in Real-World Clinical Practice

Following lower limb revascularization, optimal medical therapy includes antiplatelet agents, high-intensity statins, and control of cardiovascular risk factors. Recent studies such as COMPASS and...

How real are the adverse effects of statins? Evidence from randomized clinical trials

The safety of statins continues to be a subject of debate, partly due to the extensive list of adverse effects included in prescribing information,...

Is it safe to use negative chronotropic drugs early after TAVI?

TAVI is associated with a relevant incidence of conduction system disturbances and the development of atrioventricular block that may require permanent pacemaker implantation. Many...

Dual Antiplatelet Therapy in Diabetic Patients with AMI: De-Escalation Strategy

Diabetes Mellitus (DM) is a common comorbidity in patients hospitalized for acute coronary syndrome (ACS) of increasing prevalence over the last decade, associated with...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Low-Dose Rivaroxaban After Peripheral Angioplasty: Effectiveness and Safety in Real-World Clinical Practice

Following lower limb revascularization, optimal medical therapy includes antiplatelet agents, high-intensity statins, and control of cardiovascular risk factors. Recent studies such as COMPASS and...

Sheathless Femoral Impella: A New Strategy to Reduce Vascular Complications in High-Risk PCI?

Patients with complex coronary artery disease or cardiogenic shock undergoing percutaneous coronary intervention (PCI) may benefit from the hemodynamic support provided by percutaneous ventricular...

OCT- and IVUS-Guided Coronary Angioplasty in Acute Coronary Syndrome: Long-Term Clinical Outcomes

Percutaneous coronary angioplasty (PCI) in patients with acute coronary syndrome (ACS) has reduced mortality in the acute phase. However, recurrent ACS and target vessel...